ReviewClinical neuroradiology2026
The New Tumor Predisposition Syndromes with Neuro-Oncological Relevance-A Comprehensive Review for Neuroradiologists.
Review in Clinical neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 5th edition of the WHO Classification of Tumors of the Central Nervous System (CNS) introduced new additional tumor predisposition syndromes (TPS) that were not included in the 2016 version of the WHO Classification. It is essential for neuroradiologists to be familiar with these novel TPS entities, as accurate imaging interpretation and clinical evaluation often depend on recognising patterns of peripheral and central nervous system findings. Such identification should lead to genetic testing to confirm the suspected TPS diagnosis. Generally, neuroradiological features of brain tumors arising in these TPS are not distinctly different from those observed in sporadic forms of the same tumors. Even in uncommon cases such as meningiomas with aggressive behaviour, often seen in BAP1 syndrome, imaging and clinical evaluations can only suggest TPS; a definite diagnosis cannot be made from phenotype and imaging alone. This review discusses all new TPS in detail and presents their phenotypic spectrum known today. Knowledge of the genetic aspects of each TPS provides additional support to neuroradiologists due to the certainty of the clear distinguishability of TPS. For example, in conditions such as DICER1 syndrome and Fanconi anaemia, the diversity of genetic mutations contributes directly to the broad spectrum of phenotypic manifestations. As a result, genetic knowledge is essential not only for diagnosis but also for appreciating the complexity and heterogeneity of these syndromes in clinical practice. Finally, this discussion includes other TPS that, while not yet classified as distinct entities in the current edition of the WHO Classification of Tumors of the CNS, remain relevant to the field of neuro-oncology.
Indexed as
Identifiers
42329395What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.